GeneDx | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 114.44 M

Revenue: As of FY2026 Q2, the actual value is USD 114.44 M, beating the estimate of USD 111.01 M.

EPS: As of FY2026 Q2, the actual value is USD -0.6, beating the estimate of USD -0.715.

EBIT: As of FY2026 Q2, the actual value is USD -16.27 M.

Second Quarter 2026 Financial Highlights for GeneDx Holdings Corp.

Revenue

GeneDx Holdings Corp. reported total revenue of $114.4 million for the second quarter of 2026, an increase of 11% year-over-year. Exome and genome test revenue specifically grew to $100.3 million, marking a 17% increase year-over-year. Other panels contributed $11.6 million, data information generated $2.3 million, and software and interpretation services accounted for $0.2 million in revenue.

Operational Metrics

Exome and genome test result volume increased by 32% year-over-year, reaching 30,785 tests. The adjusted gross margin for the second quarter of 2026 was 70%, an increase from 69% in the first quarter of 2026 but a decrease from 71% in the second quarter of 2025. The GAAP gross margin stood at 68%. Adjusted total operating expenses were $80.3 million, representing 70% of revenue, while total GAAP operating expenses were $95.7 million. GeneDx Holdings Corp. reported an adjusted net income of $0.4 million, which is an increase of $8.6 million from the first quarter of 2026, but lower than the adjusted net income of $16.4 million in the second quarter of 2025. The GAAP net loss for the second quarter of 2026 was - $17.7 million, compared to GAAP net income of $10.8 million in the second quarter of 2025. The GAAP loss from operations was - $17,455 thousand, while the adjusted income from operations was $249 thousand. For the six months ended June 30, 2026, the GAAP net loss was - $81,056 thousand, compared to a GAAP net income of $4,280 thousand for the six months ended June 30, 2025.

Cash Position

As of June 30, 2026, cash, cash equivalents, marketable securities, and restricted cash totaled $133.5 million. Following an amendment to its loan agreement with Blackstone and a private placement, GeneDx Holdings Corp.’s pro forma cash position is approximately $188 million.

Cash Flow

For the six months ended June 30, 2026, net cash used in operating activities was - $61,389 thousand, a change from net cash provided by operating activities of $20,602 thousand in the prior year period. Net cash used in investing activities was - $22,885 thousand, an improvement from - $45,758 thousand in the same period of 2025. Net cash provided by financing activities increased to $39,595 thousand from $14,064 thousand year-over-year.

Outlook / Guidance

GeneDx Holdings Corp. reiterated its full-year 2026 revenue guidance of $475 million to $490 million, anticipating at least 30% exome and genome volume growth and at least 20% exome and genome revenue growth. The company expects an adjusted gross margin of approximately 70% and positive adjusted net income for the full year 2026. For the third quarter of 2026, revenue is projected between $122 million and $124 million, with an adjusted net income of approximately $2 million.